Navigation Links
Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009

Announces that Approximately 89.3 Percent of Outstanding Indevus Shares Have Been Accepted for Purchase

CHADDS FORD, Pa., March 16 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that, as of 5:00 p.m., New York City time, on March 13, 2009, approximately 71,008,964 shares (including shares delivered through notices of guaranteed delivery) were validly tendered and accepted for purchase in the tender offer by its wholly owned subsidiary, BTB Purchaser Inc., representing approximately 89.3% of the issued and outstanding shares of Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV).

Endo has extended the subsequent offering period for all of the outstanding shares of Indevus common stock until 5:00 p.m. New York City time on Wednesday, March 18, 2009. Endo and BTB do not intend to further extend the subsequent offering period, and expect to close the merger of Indevus and BTB following the expiration of the subsequent offering period.

During the extension of the subsequent offering period, BTB will accept for payment and promptly pay for Indevus shares as they are validly tendered each day. Stockholders who tender shares during such period will receive the same $4.50 per Indevus share in cash and the non-transferable contractual right to receive up to an additional $3.00 per Indevus share in cash payable upon achievement of certain regulatory and sales milestones as was paid to Indevus stockholders who previously tendered shares into the offer.

Procedures for tendering shares during this extension of the subsequent offering period shall be the same as during the subsequent offering period, including that shares may be delivered by the same guaranteed delivery procedure that was applicable during the initial offering period. Pursuant to Rule 14d-7(a)(2) under the Securities Exchange Act of 1934, as amended, shares tendered during the subsequent offering period may not be withdrawn.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at

Important Information

This press release is neither an offer to purchase nor a solicitation of an offer to sell securities. Endo Pharmaceuticals Holdings Inc. ("Endo") has filed a tender offer statement on Schedule TO with the Securities and Exchange Commission, and Indevus Pharmaceuticals, Inc. ("Indevus") has filed a solicitation/recommendation statement with respect to the tender offer. Investors and Indevus shareholders are strongly advised to read the tender offer statement (including the offer to purchase, letter of transmittal and other offer documents) and the related solicitation/recommendation statement because they contain important information. The offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, are available at no charge on the Securities and Exchange Commission's website at In addition, copies of these documents and other filings containing information about Indevus and the transaction can be obtained by all Indevus stockholders, without charge, by directing a request to Indevus Pharmaceuticals, Inc., Attention: General Counsel, 33 Hayden Avenue, Lexington, Massachusetts 02421-7966, by telephone at (781) 861-8444 or on Indevus' website,

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
3. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
5. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
6. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
7. Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
8. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
9. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
10. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
11. AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
Post Your Comments:
(Date:11/24/2015)... , ... November 24, 2015 , ... Whitehouse Laboratories is ... The new stand-alone facility will be strictly dedicated to basic USP 61, USP ... existing clients the chance to have complete chemistry and micro testing performed by one ...
(Date:11/23/2015)...   Ceres, Inc . (Nasdaq: CERE ), ... the fiscal year ended August 31, 2015 and provided ... --> During fiscal year 2015, Ceres ... with a better balance of yield, energy and nutrition. ... several leading crop input providers and made significant progress ...
(Date:11/23/2015)... ... November 23, 2015 , ... Noblis, Inc., a leading provider of science, ... Programs, National Geospatial Intelligence Agency (NGA), has joined the Noblis NSP team as President ... in the intelligence community and the private sector,” said L. Roger Mason, Jr., ...
(Date:11/23/2015)... , November 23, 2015 ... $4.27 million in 2015, and it is expected to ... 2023. The factors driving the growth of the global ... carbon sequestration property of biochar, increased government initiatives and ... government initiatives and stringent environment regulations are the key ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... announced that Google has adopted the Synaptics ® ... solutions to power its newest flagship smartphones, the Nexus ... --> --> ... to provide strategic collaboration in the joint development of ...
(Date:10/26/2015)... 26, 2015  Delta ID Inc., a company focused ... and PC devices, announced its ActiveIRIS® technology powers the ... F-02H launched by NTT DOCOMO, INC in ... second smartphone to include iris recognition technology, after a ... F-04G in May 2015, world,s first smartphone to have ...
Breaking Biology News(10 mins):